Company news
Annexin Pharmaceuticals AB news in 2026
Annexin Pharmaceuticals AB's news releases, calls and decks from 2026, newest first.
Annexin Pharmaceuticals receives the International Nonproprietary Name (INN) vanexin for the drug candidate ANXV
August 20, 2026
Annexin's rights issue 98 percent subscribed
July 3, 2026
Annexin resolves a rights issue of approximately SEK 20 million, secured to approximately 60 percent, with an overallotment option of up to approximately SEK 5 million
June 3, 2026
Annexin receives clinical trial approval in Germany, widening patient recruitment in the NEXUS study
May 11, 2026
Annexin Pharmaceuticals secures financing through bridge loan facility and plans a rights issue of approximately SEK 20 million during the summer of 2026
April 13, 2026